Health Care · Pharmaceutical Preparations

UPB Upstream Bio, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 202262653 filings
Russell 2000

UPB at a glance

Upstream Bio, Inc. (UPB, SEC CIK 2022626) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Upstream Bio, Inc. (UPB) reported revenue of $2.9 million (up 20.4% from FY2024) and a net loss of $143.4 million. Diluted EPS was -$2.66.
  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Upstream Bio, Inc. (UPB) shares worth $80.4 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Ambrose Allison on September 16, 2026 of 485 shares at $5.49 per share.
  • In the last 90 days, UPB insiders reported 0 open-market purchases ($0) and 5 open-market sales ($28K) on Form 4, a net sale of $28K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.9M
+20.4% vs prior year
Insiders · 90 days
0 buys · 5 sells
Net −$28K
13F holders
22 funds
$80.4M · −2 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New capital-raising risk: ATM Program permits up to $150.0 million, creating potential stockholder dilution
  • Financial runway: $207.4 million cash, cash equivalents and short-term investments expected to fund operations through 2027
  • New regulatory risk: FDA revised June 2026 guidance retains discretion to require additional clinical data, including a second trial
  • New privacy compliance risk: NIS 2 violations may trigger fines up to the greater of €10 million or 2% of worldwide annual turnover
  • Near-term development risk: Phase 2 CRSwNP and severe-asthma results may not translate to planned Phase 3 trials due to untested dosing regimens

Management Discussion & Analysis

  • Collaboration revenue $0.4M, down $0.3M YoY from $0.7M
  • Net loss $41.2M vs $33.7M YoY, operating loss $43.4M vs $37.8M
  • CRSwNP costs $3.5M, up $1.7M, best growth; COPD costs $9.0M, down $0.7M
  • Operating cash use $137.7M vs $102.6M YoY, investing provided $80.3M
  • Cash, equivalents and short-term investments $207.4M, funding expected through 2027; Phase 3 dosing planned Q1 2027

AI summary of the UPB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results and business highlights announced for quarter ended September 30, 2026
  • Detailed financial figures and operating updates contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Phase 3 trials in severe asthma and CRSwNP planned for Q1 2027, advancing verekitug toward late-stage development
  • Cash, equivalents and short-term investments $207.4M, expected to fund planned operations through 2027
Filed Sep 1, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Phase 3 trials planned for severe asthma and CRSwNP, marking verekitug’s transition into pivotal late-stage development
  • 400mg subcutaneous dose every 12 weeks, targeting quarterly administration and broad populations regardless of biomarker status

Item 8.01: Other Events

  • Verekitug Phase 3 plans target severe asthma and CRSwNP, advancing the asset toward pivotal efficacy and regulatory testing
  • One 400mg subcutaneous dose every 12 weeks, with approximately 1,500 patients across both placebo-controlled trials

Item 7.01: Regulation FD Disclosure

  • Upstream Bio announced pivotal Phase 3 development plans for verekitug in severe asthma
  • Verekitug development also targets chronic rhinosinusitis with nasal polyps (CRSwNP)
Filed Aug 11, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Phase 3 severe asthma and CRSwNP trials remain targeted for Q1 2027, preserving key clinical-development catalysts
  • COPD Phase 2 enrollment completed with 481 participants; data expected in the second half of 2027

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results and business highlights announced for quarter ended June 30, 2026
  • Press release furnished as Exhibit 99.1, containing the detailed financial and operational update

AI summaries of UPB 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for UPB

Don't miss the next UPB filing

  • Alerts as it files. A push when UPB files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut UPB, by share count.
  • Ask anything. An AI agent that reads every UPB filing and answers with sources.

UPB alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Ambrose AllisonSellSep 16, 2026$5.49
GRAY MICHAELSellSep 16, 2026$5.49
Sutherland Everett RandSellSep 16, 2026$5.49
Houghton AdamSellSep 16, 2026$5.49
Deykin AaronSellSep 16, 2026$5.49
Houghton AdamSellJun 16, 2026$6.10
GRAY MICHAELSellJun 16, 2026$6.10
Deykin AaronSellJun 16, 2026$6.10

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$2.4M$2.4M$2.9M
Operating Income--$77.8M-$160.4M
Net Income--$62.8M-$143.4M
Op. Margin--3281.2%-5618.8%
Net Margin--2650.0%-5026.0%
Balance Sheet
Total Assets$117.2M$481.7M$353.8M
Equity-$123.1M$469.9M$339.8M
ROE--13.4%-42.2%
Per Share
EPS$-12.95$-5.58$-2.66
Cash Flow
Operating CF--$59.2M-$133.3M
CapEx-$511K$165K

Source: XBRL data in Upstream Bio, Inc. (UPB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate UPB share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
UPB shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$80.4M
Q2 202624$147.2M
Q1 202622$167.1M
Q4 202523$446.7M
Q3 202520$286.9M
Q2 202515$145.2M
Q1 202516$54.3M
Q4 202411$144.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 153 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

UPB filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 10, 2026Analysis-
10-QNov 10, 2026Analysis
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
8-KSep 1, 2026Analysis-
8-KAug 11, 2026Analysis-
10-QAug 11, 2026-
SC 13GJul 30, 2026-
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
8-KJun 10, 2026Analysis
10-QMay 13, 2026-
8-KMay 13, 2026Analysis

Related Health Care companies

All Health Care →

UPB SEC filings: frequently asked questions

Are UPB insiders buying or selling?

In the last 90 days, Upstream Bio, Inc. (UPB) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $27,604 by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold UPB stock?

As of September 30, 2026, the largest Upstream Bio, Inc. (UPB) holders among the 13F filers tracked by SignalX were BlackRock ($19.4 million), Vanguard Capital Management LLC ($10.3 million), JPMorgan Chase & Co ($7.6 million), D.E. Shaw & Co ($7.4 million), Millennium Management ($6.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was UPB's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Upstream Bio, Inc. (UPB) reported revenue of $2.9 million (up 20.4% from FY2024) and a net loss of $143.4 million. Diluted EPS was -$2.66. The figures come from the XBRL data in the 10-K.

What did UPB report in its latest 8-K?

Upstream Bio, Inc. (UPB) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results and business highlights announced for quarter ended September 30, 2026.

What are the latest UPB SEC filings?

Upstream Bio, Inc. (UPB) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on September 17, 2026.

What is UPB's SEC CIK number?

Upstream Bio, Inc. (UPB)'s SEC Central Index Key (CIK) is 2022626. EDGAR lists every UPB filing under that number.

Ask anything about UPB

The research agent reads UPB's filings, financials, insider trades and 13F holders, then answers with sources.